Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed

키워드

참고문헌 (23)

1. Riazi K, "The prevalence and incidence of NAFLD worldwide : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 7, pp.851~861 (2022)
2. Moore JB, "COVID-19, childhood obesity, and NAFLD : colliding pandemics", Lancet Gastroenterol Hepatol, 7, pp.499~501 (2022)
3. Yu EL, "Epidemiology of pediatric nonalcoholic fatty liver disease", Clin Liver Dis(Hoboken), 17, pp.196~199 (2021)
4. Sungchul Choi, "Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study", Clinical and Molecular Hepatology, 29(2), pp.433~452 (2023), 대한간학회
5. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
6. Byrne CD, "NAFLD : a multisystem disease", J Hepatol, 62(1 Suppl), pp.S47~S64 (2015)
7. Targher G, "NAFLD and increased risk of cardiovascular disease : clinical associations, pathophysiological mechanisms and pharmacological implications", Gut, 69, pp.1691~1705 (2020)
8. Mantovani A, "Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events : an updated systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 6, pp.903~913 (2021)
9. Estes C, "Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030", J Hepatol, 69, pp.896~904 (2018)
10. Estes C, "Modelling NAFLD disease burden in four Asian regions-2019-2030", Aliment Pharmacol Ther, 51, pp.801~811 (2020)
11. Saisai Zhang, "Screening strategy for non-alcoholic fatty liver disease", Clinical and Molecular Hepatology, 29, pp.103~122 (2023), 대한간학회
12. Kasper P, "Uncontrolled hypertension : A neglected risk in patients with NAFLD", J Intern Med, 292, pp.162~164 (2022)
13. Martin A, "Management of dyslipidemia in patients with non-alcoholic fatty liver disease", Curr Atheroscler Rep, 24, pp.533~546 (2022)
14. Kasper P, "NAFLD and cardiovascular diseases : a clinical review", Clin Res Cardiol, 110, pp.921~937 (2021)
15. Sanyal AJ, "Prospective study of outcomes in adults with nonalcoholic fatty liver disease", N Engl J Med, 385, pp.1559~1569 (2021)
16. Kasper P, "Optimising the management of cardiovascular comorbidities in NAFLD patients: it’s time to (re-) act!", Gut, 71, pp.2365~2366 (2022)
17. Choi SW, "Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population : The Dong-gu study", PLoS One, 17, pp.e0277729~ (2022)
18. Simon TG, "Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease", Gut, 72, pp.573~580 (2023)
19. Newton KP, "Incidence of type 2 diabetes in children with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol (2022)[DOI]
20. Demir M, "Stepwise combination of simple noninvasive fibrosis scoring systems increases diagnostic accuracy in nonalcoholic fatty liver disease", J Clin Gastroenterol, 47, pp.719~726 (2013)
21. Park H, "Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population", Front Med(Lausanne), 9, pp.1024836~ (2022)
22. Shah S, "FIB-4 cut-off of 1. 3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease", J Hepatol, 73, pp.216~217 (2020)
23. McPherson S, "Age as a confounding factor for the accurate noninvasive diagnosis of advanced NAFLD fibrosis", Am J Gastroenterol, 112, pp.740~751 (2017)

관련 논문AI추천